Ολανζαπίνη (Greek Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ολανζαπίνη" in Greek language version.

refsWebsite

Global rank Greek rank

57nih.gov

4^th place

44doi.org

2^nd place

3^rd place

8web.archive.org

1^st place

7archive.org

6^th place

5^th place

4worldcat.org

5^th place

8^th place

3drugs.com

399^th place

130^th place

3books.google.com

3^rd place

6^th place

3nice.org.uk

3,258^th place

2,509^th place

2clincalc.com

3,912^th place

594^th place

2madinamerica.com

low place

2medscape.com

719^th place

579^th place

1aspetjournals.org

6,663^rd place

9,745^th place

1tga.gov.au

3,984^th place

2,133^rd place

1in.gov.br

3,151^st place

low place

1tum.de

7,448^th place

low place

1stutteringhelp.org

low place

1researchautism.net

low place

1zyprexa.com

low place

1bbc.co.uk

8^th place

20^th place

1medicinescomplete.com

low place

5,144^th place

1medicines.org.uk

3,823^rd place

2,141^st place

1astrazenecaclinicaltrials.com

low place

1nytimes.com

7^th place

29^th place

1rxlist.com

7,927^th place

3,123^rd place

1lilly.com

low place

1pharmacytimes.com

low place

1cancer.gov

1,684^th place

784^th place

archive.org

The Maudsley prescribing guidelines in psychiatry. Wiley-Blackwell. 2012.
«Maternal obesity and risk of neural tube defects: a metaanalysis». American Journal of Obstetrics & Gynecology 198 (6): 611–619. June 2008. doi:10.1016/j.ajog.2008.04.021. PMID 18538144. https://archive.org/details/sim_american-journal-of-obstetrics-and-gynecology_2008-06_198_6/page/611.
«Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison». The American Journal of Psychiatry 164 (7): 1050–60. July 2007. doi:10.1176/ajp.2007.164.7.1050. PMID 17606657. https://archive.org/details/sim_american-journal-of-psychiatry_2007-07_164_7/page/1050.
«Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets». Psychopharmacology 175 (3): 389–90. 2004. doi:10.1007/s00213-004-1951-2. PMID 15322727. https://archive.org/details/sim_psychopharmacology_2004-09_175_3/page/389.
Joint Formulary Committee, BMJ, επιμ. (Μαρτίου 2009). «4.2.1». British National Formulary (57 έκδοση). United Kingdom: Royal Pharmaceutical Society of Great Britain. σελ. 192. ISBN 978-0-85369-845-6. Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.
«Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein». Psychopharmacology 187 (4): 415–423. September 2006. doi:10.1007/s00213-006-0437-9. PMID 16810505. https://archive.org/details/sim_psychopharmacology_2006-09_187_4/page/415.
«Inhibitory Effects of Antipsychotics on Carbachol-Enhanced Insulin Secretion from Perifused Rat Islets: Role of Muscarinic Antagonism in Antipsychotic-Induced Diabetes and Hyperglycemia». Diabetes 54 (5): 1552–8. 2005. doi:10.2337/diabetes.54.5.1552. PMID 15855345. https://archive.org/details/sim_diabetes_2005-05_54_5/page/1552.

aspetjournals.org

dmd.aspetjournals.org

«Disposition and biotransformation of the antipsychotic agent olanzapine in humans». Drug Metabolism and Disposition 25 (1): 81–93. January 1997. PMID 9010634. http://dmd.aspetjournals.org/content/25/1/81.long.

astrazenecaclinicaltrials.com

AstraZeneca Pharmaceuticals (4 Απριλίου 2006). «Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomised Double Blind 52 Week Comparison». AstraZeneca Clinical Trials. AstraZeneca PLC. Αρχειοθετήθηκε από το πρωτότυπο στις 13 Νοεμβρίου 2007. Ανακτήθηκε στις 3 Δεκεμβρίου 2007. At week 12, the olanzapine-treated group had more weight gain, a higher increase in [ body mass index ], and a higher proportion of patients with a BMI increase of at least 1 unit compared with the quetiapine and risperidone groups (p<=0.01).

bbc.co.uk

news.bbc.co.uk

«Doctors 'ignoring drugs warning'». BBC News. 17 June 2008. http://news.bbc.co.uk/1/hi/programmes/file_on_4/7457132.stm. Ανακτήθηκε στις 2008-06-22.

books.google.com

The Maudsley Prescribing Guidelines in Psychiatry (12th έκδοση). London, U K: Wiley-Blackwell. 2015. σελ. 16. ISBN 978-1-118-75460-3.
Haddad, Peter· Haddad, Peter M. (2004). Adverse Syndromes and Psychiatric Drugs: A Clinical Guide (στα Αγγλικά). OUP Oxford. σελίδες 207–216. ISBN 9780198527480.
Sacchetti, Emilio· Vita, Antonio (2013). Adherence to Antipsychotics in Schizophrenia (στα Αγγλικά). Springer Science & Business Media. σελ. 85. ISBN 9788847026797.

cancer.gov

«olanzapine». NCI Drug Dictionary. National Cancer Institute. 2 Φεβρουαρίου 2011.

clincalc.com

«The Top 300 of 2020». ClinCalc. Ανακτήθηκε στις 11 Απριλίου 2020.
«Olanzapine - Drug Usage Statistics». ClinCalc. Ανακτήθηκε στις 11 Απριλίου 2020.

doi.org

dx.doi.org

«Olanzapine. Pharmacokinetic and pharmacodynamic profile». Clinical Pharmacokinetics 37 (3): 177–193. September 1999. doi:10.2165/00003088-199937030-00001. PMID 10511917.
«Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response». Clinical Pharmacokinetics 46 (5): 359–388. 2007. doi:10.2165/00003088-200746050-00001. PMID 17465637.
«Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis». Lancet 382 (9896): 951–62. September 2013. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019.
«A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia». CNS Drugs 30 (1): 27–39. January 2016. doi:10.1007/s40263-015-0308-1. PMID 26801655.
«Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis». Journal of the American Academy of Child and Adolescent Psychiatry 56 (3): 191–202. March 2017. doi:10.1016/j.jaac.2016.12.013. PMID 28219485.
«The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia». Harvard Review of Psychiatry 21 (1): 18–40. 2013. doi:10.1097/HRP.0b013e31827fd915. PMID 23656760.
«Olanzapine for schizophrenia». The Cochrane Database of Systematic Reviews (2): CD001359. April 2005. doi:10.1002/14651858.CD001359.pub2. PMID 15846619.
«Olanzapine versus other atypical antipsychotics for schizophrenia». The Cochrane Database of Systematic Reviews (3): CD006654. March 2010. doi:10.1002/14651858.CD006654.pub2. PMID 20238348.
«Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology». J. Psychopharmacol. (Oxford) 25 (5): 567–620. 2011. doi:10.1177/0269881110391123. PMID 21292923. http://mediatum.ub.tum.de/doc/1100004/document.pdf. ^{[νεκρός σύνδεσμος]}
«World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects». World J. Biol. Psychiatry 14 (1): 2–44. 2013. doi:10.3109/15622975.2012.739708. PMID 23216388.
«Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis». Int. J. Neuropsychopharmacol. 16 (6): 1205–18. July 2013. doi:10.1017/S1461145712001277. PMID 23199972.
«A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia». Expert Opin Pharmacother 13 (11): 1545–73. August 2012. doi:10.1517/14656566.2011.626769. PMID 21999805.
«Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis». European Journal of Clinical Pharmacology 70 (2): 127–34. February 2014. doi:10.1007/s00228-013-1600-y. PMID 24145817.
«Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics». Pharmacopsychiatry 47 (2): 43–52. March 2014. doi:10.1055/s-0033-1363258. PMID 24549862.
«Off-label use of atypical antipsychotic agents for treatment of insomnia». Mental Health Clinician 4 (2): 65–72. March 2014. doi:10.9740/mhc.n190091.
«Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update». Journal of Clinical Oncology 35 (28): 3240–3261. October 2017. doi:10.1200/JCO.2017.74.4789. PMID 28759346.
«Maternal obesity and risk of neural tube defects: a metaanalysis». American Journal of Obstetrics & Gynecology 198 (6): 611–619. June 2008. doi:10.1016/j.ajog.2008.04.021. PMID 18538144. https://archive.org/details/sim_american-journal-of-obstetrics-and-gynecology_2008-06_198_6/page/611.
«Maternal obesity, folate intake, and neural tube defects in offspring». Birth Defects Research Part A: Clinical and Molecular Teratology 97 (2): 115–122. February 2013. doi:10.1002/bdra.23113. PMID 23404872.
«Effect of atypical antipsychotics on body weight in geriatric psychiatric inpatients». SAGE Open Medicine 5: 2050312117708711. 2017-05-08. doi:10.1177/2050312117708711. PMID 28540050.
«Heat-related side-effects of neurological and non-neurological medication may increase heatwave fatalities». European Journal of Neurology 16 (7): 879–82. July 2009. doi:10.1111/j.1468-1331.2009.02581.x. PMID 19453697.
«Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia». Archives of General Psychiatry 68 (2): 128–37. February 2011. doi:10.1001/archgenpsychiatry.2010.199. PMID 21300943.
«The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys». Neuropsychopharmacology 30 (9): 1649–61. September 2005. doi:10.1038/sj.npp.1300710. PMID 15756305.
Alevizos, Basil; Papageorgiou, Charalambos; Christodoulou, George N. (1 September 2004). «Obsessive-compulsive symptoms with olanzapine». The International Journal of Neuropsychopharmacology 7 (3): 375–377. doi:10.1017/S1461145704004456. ISSN 1461-1457. PMID 15231024.
Kulkarni, Gajanan; Narayanaswamy, Janardhanan C.; Math, Suresh Bada (1 January 2012). «Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia». Indian Journal of Pharmacology 44 (5): 649–650. doi:10.4103/0253-7613.100406. ISSN 0253-7613. PMID 23112432.
Lykouras, L.; Zervas, I. M.; Gournellis, R.; Malliori, M.; Rabavilas, A. (1 September 2000). «Olanzapine and obsessive-compulsive symptoms». European Neuropsychopharmacology 10 (5): 385–387. doi:10.1016/s0924-977x(00)00096-1. ISSN 0924-977X. PMID 10974610.
Schirmbeck, Frederike; Zink, Mathias (1 March 2012). «Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Critical Review». Current Neuropharmacology 10 (1): 88–95. doi:10.2174/157015912799362724. ISSN 1570-159X. PMID 22942882.
«Olanzapine-induced destabilization of diabetes in the absence of weight gain». Acta Psychiatrica Scandinavica 105 (3): 235–6; discussion 236–7. 2002. doi:10.1034/j.1600-0447.2002.2c257a.x. PMID 11939979.
«New-onset type-2 diabetes associated with atypical antipsychotic medications». Progress in Neuro-Psychopharmacology and Biological Psychiatry 30 (5): 919–23. 2006. doi:10.1016/j.pnpbp.2006.02.007. PMID 16581171.
«Novel Antipsychotics». The Journal of Clinical Psychiatry 60 (6): 358–63. 1999. doi:10.4088/JCP.v60n0602. PMID 10401912.
«Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison». The American Journal of Psychiatry 164 (7): 1050–60. July 2007. doi:10.1176/ajp.2007.164.7.1050. PMID 17606657. https://archive.org/details/sim_american-journal-of-psychiatry_2007-07_164_7/page/1050.
«Complete Resolution of Olanzapine-Induced Diabetic Ketoacidosis». Journal of Pharmacy Practice 19 (4): 255–8. 2006. doi:10.1177/0897190006294180.
«The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine». Progress in Neuro-Psychopharmacology & Biological Psychiatry 34 (6): 866–70. August 2010. doi:10.1016/j.pnpbp.2010.04.003. PMID 20394794.
«Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers». Neuropsychopharmacology 33 (7): 1633–41. June 2008. doi:10.1038/sj.npp.1301541. PMID 17712347.
«Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp». The Journal of Clinical Endocrinology and Metabolism 88 (12): 5875–80. December 2003. doi:10.1210/jc.2002-021884. PMID 14671184.
«Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets». Psychopharmacology 175 (3): 389–90. 2004. doi:10.1007/s00213-004-1951-2. PMID 15322727. https://archive.org/details/sim_psychopharmacology_2004-09_175_3/page/389.
«Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management». CNS Drugs 29 (1): 41–6. January 2015. doi:10.1007/s40263-014-0216-9. PMID 25424243.
«Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse». Acta Psychiatrica Scandinavica 114 (1): 3–13. July 2006. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655.
«Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?». Clinical Pharmacokinetics 50 (7): 415–28. July 2011. doi:10.2165/11587240-000000000-00000. PMID 21651311.
«Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein». Psychopharmacology 187 (4): 415–423. September 2006. doi:10.1007/s00213-006-0437-9. PMID 16810505. https://archive.org/details/sim_psychopharmacology_2006-09_187_4/page/415.
«Relationship between P-glycoprotein and second-generation antipsychotics». Pharmacogenomics 12 (8): 1193–1211. August 2011. doi:10.2217/pgs.11.55. PMID 21843066.
«Inhibitory Effects of Antipsychotics on Carbachol-Enhanced Insulin Secretion from Perifused Rat Islets: Role of Muscarinic Antagonism in Antipsychotic-Induced Diabetes and Hyperglycemia». Diabetes 54 (5): 1552–8. 2005. doi:10.2337/diabetes.54.5.1552. PMID 15855345. https://archive.org/details/sim_diabetes_2005-05_54_5/page/1552.
«Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor». CNS Drugs 27 (12): 1069–1080. 10 October 2013. doi:10.1007/s40263-013-0115-5. PMID 24114586.
«Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes». Methods and Findings in Experimental and Clinical Pharmacology 27 (5): 289–304. 2005. doi:10.1358/mf.2005.27.5.908643. PMID 16082416.
«Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain». Pharmacogenomics and Personalized Medicine 4: 83–93. 2011-08-18. doi:10.2147/PGPM.S11866. PMID 23226055.

drugs.com

«Olanzapine, Olanzapine Pamoate Monograph for Professionals». Drugs.com (στα Αγγλικά). AHFS. Ανακτήθηκε στις 24 Δεκεμβρίου 2018.
«Olanzapine Monograph for Professionals - Drugs.com». Drugs.com. Ανακτήθηκε στις 24 Μαρτίου 2017.
Cerner Multum Incorporated (27 Σεπτεμβρίου 2011). «Olanzapine». Drugs.com.

in.gov.br

Anvisa (31 Μαρτίου 2023). «RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial» [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (στα Πορτογαλικά). Diário Oficial da União (δημοσιεύτηκε 4 Απριλίου 2023). Αρχειοθετήθηκε από το πρωτότυπο στις 3 Αυγούστου 2023. Ανακτήθηκε στις 16 Αυγούστου 2023.

lilly.com

pi.lilly.com

«Olanzapine Prescribing Information» (PDF). Eli Lilly and Company. 19 Μαρτίου 2009. Ανακτήθηκε στις 6 Σεπτεμβρίου 2009.

madinamerica.com

Simons, Peter (6 Ιουλίου 2020). «Randomized Controlled Trial Confirms That Antipsychotics Damage the Brain». Mad In America (στα Αγγλικά). Ανακτήθηκε στις 25 Αυγούστου 2020.
Simons, Peter (27 Νοεμβρίου 2018). «Researchers Warn of "Brain Atrophy" in Children Prescribed Antipsychotics». Mad In America (στα Αγγλικά). Ανακτήθηκε στις 25 Αυγούστου 2020.

medicines.org.uk

«Olanzapine 10 mg tablets - Summary of Product Characteristics (SPC)». electronic Medicines Compendium. Aurobindo Pharma - Milpharm Ltd. 17 Μαΐου 2013. Αρχειοθετήθηκε από το πρωτότυπο στις 2 Δεκεμβρίου 2013. Ανακτήθηκε στις 26 Νοεμβρίου 2013.

medicinescomplete.com

Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press http://www.medicinescomplete.com [Accessed on 2nd February 2020]

medscape.com

reference.medscape.com

«Zyprexa, Zyprexa Relprevv (olanzapine) dosing, indications, interactions, adverse effects, and more». Medscape Reference. WebMD. Ανακτήθηκε στις 26 Νοεμβρίου 2013.

medscape.com

Moyer, Paula (Oct 25, 2005). «CAFE Study Shows Varying Benefits Among Atypical Antipsychotics». Medscape Medical News (WebMD). http://www.medscape.com/viewarticle/515435. Ανακτήθηκε στις 2007-12-03.

nice.org.uk

National Collaborating Centre for Mental Health (25 Μαρτίου 2009). «Schizophrenia: Full national clinical guideline on core interventions in primary and secondary care» (PDF). Ανακτήθηκε στις 25 Νοεμβρίου 2009.
«Psychosis and schizophrenia in adults: treatment and management | Guidance and guidelines | NICE». National Institute for Health and Care Excellence.
«Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care | 1-recommendations | Guidance and guidelines | NICE». Ανακτήθηκε στις 26 Ιουλίου 2016.

nih.gov

ncbi.nlm.nih.gov

«Disposition and biotransformation of the antipsychotic agent olanzapine in humans». Drug Metabolism and Disposition 25 (1): 81–93. January 1997. PMID 9010634. http://dmd.aspetjournals.org/content/25/1/81.long.
«Olanzapine. Pharmacokinetic and pharmacodynamic profile». Clinical Pharmacokinetics 37 (3): 177–193. September 1999. doi:10.2165/00003088-199937030-00001. PMID 10511917.
«Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response». Clinical Pharmacokinetics 46 (5): 359–388. 2007. doi:10.2165/00003088-200746050-00001. PMID 17465637.
«Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis». Lancet 382 (9896): 951–62. September 2013. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019.
«A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia». CNS Drugs 30 (1): 27–39. January 2016. doi:10.1007/s40263-015-0308-1. PMID 26801655.
«Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis». Journal of the American Academy of Child and Adolescent Psychiatry 56 (3): 191–202. March 2017. doi:10.1016/j.jaac.2016.12.013. PMID 28219485.
«The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia». Harvard Review of Psychiatry 21 (1): 18–40. 2013. doi:10.1097/HRP.0b013e31827fd915. PMID 23656760.
«Olanzapine for schizophrenia». The Cochrane Database of Systematic Reviews (2): CD001359. April 2005. doi:10.1002/14651858.CD001359.pub2. PMID 15846619.
«Olanzapine versus other atypical antipsychotics for schizophrenia». The Cochrane Database of Systematic Reviews (3): CD006654. March 2010. doi:10.1002/14651858.CD006654.pub2. PMID 20238348.
«Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology». J. Psychopharmacol. (Oxford) 25 (5): 567–620. 2011. doi:10.1177/0269881110391123. PMID 21292923. http://mediatum.ub.tum.de/doc/1100004/document.pdf. ^{[νεκρός σύνδεσμος]}
«World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects». World J. Biol. Psychiatry 14 (1): 2–44. 2013. doi:10.3109/15622975.2012.739708. PMID 23216388.
First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness [Internet]. August 2012. PMID 23035275.
«Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis». Int. J. Neuropsychopharmacol. 16 (6): 1205–18. July 2013. doi:10.1017/S1461145712001277. PMID 23199972.
«A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia». Expert Opin Pharmacother 13 (11): 1545–73. August 2012. doi:10.1517/14656566.2011.626769. PMID 21999805.
«Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis». European Journal of Clinical Pharmacology 70 (2): 127–34. February 2014. doi:10.1007/s00228-013-1600-y. PMID 24145817.
«Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics». Pharmacopsychiatry 47 (2): 43–52. March 2014. doi:10.1055/s-0033-1363258. PMID 24549862.
Off-Label Use of Atypical Antipsychotics: An Update. AHRQ Comparative Effectiveness Reviews. Agency for Healthcare Research and Quality (US). 2011. PMID 22132426. https://www.ncbi.nlm.nih.gov/books/NBK66081/.
«Review of olanzapine in the management of bipolar disorders». Neuropsychiatr Dis Treat 3 (5): 579–587. October 2007. PMID 19300587.
«Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update». Journal of Clinical Oncology 35 (28): 3240–3261. October 2017. doi:10.1200/JCO.2017.74.4789. PMID 28759346.
«Maternal obesity and risk of neural tube defects: a metaanalysis». American Journal of Obstetrics & Gynecology 198 (6): 611–619. June 2008. doi:10.1016/j.ajog.2008.04.021. PMID 18538144. https://archive.org/details/sim_american-journal-of-obstetrics-and-gynecology_2008-06_198_6/page/611.
«Maternal obesity, folate intake, and neural tube defects in offspring». Birth Defects Research Part A: Clinical and Molecular Teratology 97 (2): 115–122. February 2013. doi:10.1002/bdra.23113. PMID 23404872.
«Effect of atypical antipsychotics on body weight in geriatric psychiatric inpatients». SAGE Open Medicine 5: 2050312117708711. 2017-05-08. doi:10.1177/2050312117708711. PMID 28540050.
«Heat-related side-effects of neurological and non-neurological medication may increase heatwave fatalities». European Journal of Neurology 16 (7): 879–82. July 2009. doi:10.1111/j.1468-1331.2009.02581.x. PMID 19453697.
«Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia». Archives of General Psychiatry 68 (2): 128–37. February 2011. doi:10.1001/archgenpsychiatry.2010.199. PMID 21300943.
«The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys». Neuropsychopharmacology 30 (9): 1649–61. September 2005. doi:10.1038/sj.npp.1300710. PMID 15756305.
Alevizos, Basil; Papageorgiou, Charalambos; Christodoulou, George N. (1 September 2004). «Obsessive-compulsive symptoms with olanzapine». The International Journal of Neuropsychopharmacology 7 (3): 375–377. doi:10.1017/S1461145704004456. ISSN 1461-1457. PMID 15231024.
Kulkarni, Gajanan; Narayanaswamy, Janardhanan C.; Math, Suresh Bada (1 January 2012). «Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia». Indian Journal of Pharmacology 44 (5): 649–650. doi:10.4103/0253-7613.100406. ISSN 0253-7613. PMID 23112432.
Lykouras, L.; Zervas, I. M.; Gournellis, R.; Malliori, M.; Rabavilas, A. (1 September 2000). «Olanzapine and obsessive-compulsive symptoms». European Neuropsychopharmacology 10 (5): 385–387. doi:10.1016/s0924-977x(00)00096-1. ISSN 0924-977X. PMID 10974610.
Schirmbeck, Frederike; Zink, Mathias (1 March 2012). «Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Critical Review». Current Neuropharmacology 10 (1): 88–95. doi:10.2174/157015912799362724. ISSN 1570-159X. PMID 22942882.
«Olanzapine-induced destabilization of diabetes in the absence of weight gain». Acta Psychiatrica Scandinavica 105 (3): 235–6; discussion 236–7. 2002. doi:10.1034/j.1600-0447.2002.2c257a.x. PMID 11939979.
«New-onset type-2 diabetes associated with atypical antipsychotic medications». Progress in Neuro-Psychopharmacology and Biological Psychiatry 30 (5): 919–23. 2006. doi:10.1016/j.pnpbp.2006.02.007. PMID 16581171.
«Novel Antipsychotics». The Journal of Clinical Psychiatry 60 (6): 358–63. 1999. doi:10.4088/JCP.v60n0602. PMID 10401912.
«Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison». The American Journal of Psychiatry 164 (7): 1050–60. July 2007. doi:10.1176/ajp.2007.164.7.1050. PMID 17606657. https://archive.org/details/sim_american-journal-of-psychiatry_2007-07_164_7/page/1050.
«Dosing the antipsychotic medication olanzapine». The Journal of Clinical Psychiatry 58 Suppl 10 (Suppl 10): 45–9. 1997. PMID 9265916.
«The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine». Progress in Neuro-Psychopharmacology & Biological Psychiatry 34 (6): 866–70. August 2010. doi:10.1016/j.pnpbp.2010.04.003. PMID 20394794.
«Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers». Neuropsychopharmacology 33 (7): 1633–41. June 2008. doi:10.1038/sj.npp.1301541. PMID 17712347.
«Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp». The Journal of Clinical Endocrinology and Metabolism 88 (12): 5875–80. December 2003. doi:10.1210/jc.2002-021884. PMID 14671184.
«Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets». Psychopharmacology 175 (3): 389–90. 2004. doi:10.1007/s00213-004-1951-2. PMID 15322727. https://archive.org/details/sim_psychopharmacology_2004-09_175_3/page/389.
«Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management». CNS Drugs 29 (1): 41–6. January 2015. doi:10.1007/s40263-014-0216-9. PMID 25424243.
«Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse». Acta Psychiatrica Scandinavica 114 (1): 3–13. July 2006. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655.
«Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?». Clinical Pharmacokinetics 50 (7): 415–28. July 2011. doi:10.2165/11587240-000000000-00000. PMID 21651311.
«Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein». Psychopharmacology 187 (4): 415–423. September 2006. doi:10.1007/s00213-006-0437-9. PMID 16810505. https://archive.org/details/sim_psychopharmacology_2006-09_187_4/page/415.
«Relationship between P-glycoprotein and second-generation antipsychotics». Pharmacogenomics 12 (8): 1193–1211. August 2011. doi:10.2217/pgs.11.55. PMID 21843066.
«Inhibitory Effects of Antipsychotics on Carbachol-Enhanced Insulin Secretion from Perifused Rat Islets: Role of Muscarinic Antagonism in Antipsychotic-Induced Diabetes and Hyperglycemia». Diabetes 54 (5): 1552–8. 2005. doi:10.2337/diabetes.54.5.1552. PMID 15855345. https://archive.org/details/sim_diabetes_2005-05_54_5/page/1552.
«Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor». CNS Drugs 27 (12): 1069–1080. 10 October 2013. doi:10.1007/s40263-013-0115-5. PMID 24114586.
«Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes». Methods and Findings in Experimental and Clinical Pharmacology 27 (5): 289–304. 2005. doi:10.1358/mf.2005.27.5.908643. PMID 16082416.
«Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain». Pharmacogenomics and Personalized Medicine 4: 83–93. 2011-08-18. doi:10.2147/PGPM.S11866. PMID 23226055.

pubmedcentral.nih.gov

«Olanzapine versus other atypical antipsychotics for schizophrenia». The Cochrane Database of Systematic Reviews (3): CD006654. March 2010. doi:10.1002/14651858.CD006654.pub2. PMID 20238348.
«Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis». Int. J. Neuropsychopharmacol. 16 (6): 1205–18. July 2013. doi:10.1017/S1461145712001277. PMID 23199972.
«Review of olanzapine in the management of bipolar disorders». Neuropsychiatr Dis Treat 3 (5): 579–587. October 2007. PMID 19300587.
«Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update». Journal of Clinical Oncology 35 (28): 3240–3261. October 2017. doi:10.1200/JCO.2017.74.4789. PMID 28759346.
«Effect of atypical antipsychotics on body weight in geriatric psychiatric inpatients». SAGE Open Medicine 5: 2050312117708711. 2017-05-08. doi:10.1177/2050312117708711. PMID 28540050.
«Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia». Archives of General Psychiatry 68 (2): 128–37. February 2011. doi:10.1001/archgenpsychiatry.2010.199. PMID 21300943.
Kulkarni, Gajanan; Narayanaswamy, Janardhanan C.; Math, Suresh Bada (1 January 2012). «Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia». Indian Journal of Pharmacology 44 (5): 649–650. doi:10.4103/0253-7613.100406. ISSN 0253-7613. PMID 23112432.
Schirmbeck, Frederike; Zink, Mathias (1 March 2012). «Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Critical Review». Current Neuropharmacology 10 (1): 88–95. doi:10.2174/157015912799362724. ISSN 1570-159X. PMID 22942882.
«Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain». Pharmacogenomics and Personalized Medicine 4: 83–93. 2011-08-18. doi:10.2147/PGPM.S11866. PMID 23226055.

dailymed.nlm.nih.gov

«OLANZAPINE (olanzapine) tablet OLANZAPINE (olanzapine) tablet, orally disintegrating [Prasco Laboratories]». DailyMed. Prasco Laboratories. Σεπτεμβρίου 2013. Αρχειοθετήθηκε από το πρωτότυπο στις 5 Ιουλίου 2013. Ανακτήθηκε στις 26 Νοεμβρίου 2013.

nytimes.com

Carey, Benedict (September 20, 2005). «Little Difference Found in Schizophrenia Drugs». The New York Times. https://www.nytimes.com/2005/09/20/health/psychology/20drug.html. Ανακτήθηκε στις 2007-12-03.

pharmacytimes.com

«Drug Transporters: The Final Frontier for Drug Interactions». Pharmacy Times. December 1, 2008. Αρχειοθετήθηκε από το πρωτότυπο στις 2017-02-11. https://web.archive.org/web/20170211080820/http://www.pharmacytimes.com/publications/issue/2008/2008-12/2008-12-8474. Ανακτήθηκε στις 2020-09-18.

researchautism.net

«Olanzapine and Autism». Research Autism. 19 Δεκεμβρίου 2017. Ανακτήθηκε στις 9 Ιουνίου 2018.

rxlist.com

«Symbyax (Olanzapine and fluoxetine) drug overdose and contraindication information». RxList: The Internet Drug Index. WebMD. 2007. Αρχειοθετήθηκε από το πρωτότυπο στις 14 Δεκεμβρίου 2007. Ανακτήθηκε στις 3 Δεκεμβρίου 2007.

stutteringhelp.org

Scott, Lisa (Winter 2006). «Genetic and Neurological Factors in Stuttering». Stuttering Foundation of America. Αρχειοθετήθηκε από το πρωτότυπο στις 28 Ιουλίου 2011. Ανακτήθηκε στις 18 Σεπτεμβρίου 2020.

tga.gov.au

ebs.tga.gov.au

«PRODUCT INFORMATION OLANZAPINE SANDOZ® 2.5mg/5mg/7.5mg/10mg/15mg/20mg FILM-COATED TABLETS» (PDF). TGA eBusiness Services. Sandoz Pty Ltd. 8 Ιουνίου 2012. Ανακτήθηκε στις 26 Νοεμβρίου 2013.

tum.de

mediatum.ub.tum.de

«Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology». J. Psychopharmacol. (Oxford) 25 (5): 567–620. 2011. doi:10.1177/0269881110391123. PMID 21292923. http://mediatum.ub.tum.de/doc/1100004/document.pdf. ^{[νεκρός σύνδεσμος]}

web.archive.org

Anvisa (31 Μαρτίου 2023). «RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial» [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (στα Πορτογαλικά). Diário Oficial da União (δημοσιεύτηκε 4 Απριλίου 2023). Αρχειοθετήθηκε από το πρωτότυπο στις 3 Αυγούστου 2023. Ανακτήθηκε στις 16 Αυγούστου 2023.
Scott, Lisa (Winter 2006). «Genetic and Neurological Factors in Stuttering». Stuttering Foundation of America. Αρχειοθετήθηκε από το πρωτότυπο στις 28 Ιουλίου 2011. Ανακτήθηκε στις 18 Σεπτεμβρίου 2020.
«Important Safety Information for Olanzapine». Zyprexa package insert. Eli Lilly & Company. 2007. Αρχειοθετήθηκε από το πρωτότυπο στις 23 Νοεμβρίου 2007. Ανακτήθηκε στις 3 Δεκεμβρίου 2007. Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. [...] ZYPREXA (olanzapine) is not approved for the treatment of elderly patients with dementia-related psychosis.
«OLANZAPINE (olanzapine) tablet OLANZAPINE (olanzapine) tablet, orally disintegrating [Prasco Laboratories]». DailyMed. Prasco Laboratories. Σεπτεμβρίου 2013. Αρχειοθετήθηκε από το πρωτότυπο στις 5 Ιουλίου 2013. Ανακτήθηκε στις 26 Νοεμβρίου 2013.
«Olanzapine 10 mg tablets - Summary of Product Characteristics (SPC)». electronic Medicines Compendium. Aurobindo Pharma - Milpharm Ltd. 17 Μαΐου 2013. Αρχειοθετήθηκε από το πρωτότυπο στις 2 Δεκεμβρίου 2013. Ανακτήθηκε στις 26 Νοεμβρίου 2013.
AstraZeneca Pharmaceuticals (4 Απριλίου 2006). «Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomised Double Blind 52 Week Comparison». AstraZeneca Clinical Trials. AstraZeneca PLC. Αρχειοθετήθηκε από το πρωτότυπο στις 13 Νοεμβρίου 2007. Ανακτήθηκε στις 3 Δεκεμβρίου 2007. At week 12, the olanzapine-treated group had more weight gain, a higher increase in [ body mass index ], and a higher proportion of patients with a BMI increase of at least 1 unit compared with the quetiapine and risperidone groups (p<=0.01).
«Symbyax (Olanzapine and fluoxetine) drug overdose and contraindication information». RxList: The Internet Drug Index. WebMD. 2007. Αρχειοθετήθηκε από το πρωτότυπο στις 14 Δεκεμβρίου 2007. Ανακτήθηκε στις 3 Δεκεμβρίου 2007.
«Drug Transporters: The Final Frontier for Drug Interactions». Pharmacy Times. December 1, 2008. Αρχειοθετήθηκε από το πρωτότυπο στις 2017-02-11. https://web.archive.org/web/20170211080820/http://www.pharmacytimes.com/publications/issue/2008/2008-12/2008-12-8474. Ανακτήθηκε στις 2020-09-18.

worldcat.org

Alevizos, Basil; Papageorgiou, Charalambos; Christodoulou, George N. (1 September 2004). «Obsessive-compulsive symptoms with olanzapine». The International Journal of Neuropsychopharmacology 7 (3): 375–377. doi:10.1017/S1461145704004456. ISSN 1461-1457. PMID 15231024.
Kulkarni, Gajanan; Narayanaswamy, Janardhanan C.; Math, Suresh Bada (1 January 2012). «Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia». Indian Journal of Pharmacology 44 (5): 649–650. doi:10.4103/0253-7613.100406. ISSN 0253-7613. PMID 23112432.
Lykouras, L.; Zervas, I. M.; Gournellis, R.; Malliori, M.; Rabavilas, A. (1 September 2000). «Olanzapine and obsessive-compulsive symptoms». European Neuropsychopharmacology 10 (5): 385–387. doi:10.1016/s0924-977x(00)00096-1. ISSN 0924-977X. PMID 10974610.
Schirmbeck, Frederike; Zink, Mathias (1 March 2012). «Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Critical Review». Current Neuropharmacology 10 (1): 88–95. doi:10.2174/157015912799362724. ISSN 1570-159X. PMID 22942882.

zyprexa.com

«Important Safety Information for Olanzapine». Zyprexa package insert. Eli Lilly & Company. 2007. Αρχειοθετήθηκε από το πρωτότυπο στις 23 Νοεμβρίου 2007. Ανακτήθηκε στις 3 Δεκεμβρίου 2007. Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. [...] ZYPREXA (olanzapine) is not approved for the treatment of elderly patients with dementia-related psychosis.